

Contents lists available at ScienceDirect

Journal of Neuroimmunology



journal homepage: www.elsevier.com/locate/jneuroim

Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers

Ivan Adamec^{a,b}, Gregor Brecl Jakob^{c,d}, Cecilia Rajda^e, Jelena Drulović^{f,g}, Ljiljana Radulović^h, Vanja Bašić Kesⁱ, Ines Lazibat^j, Julija Rimac^k, Igor Cindrić¹, Tihana Gržinčić^m, Ana Abičićⁿ, Barbara Barun^{a,b}, Tereza Gabelić^{a,b}, Sarah Gomezelj^c, Šarlota Mesaroš^{f,g}, Tatjana Pekmezović^o, Péter Klivényi^e, Magdalena Krbot Skorić^{a,p}, Mario Habek^{a,b,*}

^a Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia

- ^c Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia
- ^d Faculty of Medicine, University of Ljubljana, Slovenia

^h Department of Neurology, Clinical Center of Montenegro, Podgorica, Montenegro

ⁱ Department of Neurology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

- ^j Department of Neurology, University Hospital Dubrava, Zagreb, Croatia
- ^k Department of Neurology, National Memorial Hospital "dr. Juraj Njavro" Vukovar, Vukovar, Croatia
- ¹ Department of Neurology, General Hospital Virovitica, Virovitica, Croatia
- ^m Department of Neurology, General Hospital Bjelovar, Bjelovar, Croatia

ⁿ General Hospital Zabok, Zabok, Croatia

- ° Faculty of Medicine, Institute of Epidemiology, University of Belgrade, Belgrade, Serbia
- ^p Faculty of Electrical Engineering and Computing, University of Zagreb, Zagreb, Croatia

ARTICLE INFO

Keywords: Cladribine Multiple sclerosis Real-world data

ABSTRACT

Background: Cladribine is an oral disease-modifying drug authorized by the European Medicine Agency for the treatment of highly active relapsing multiple sclerosis (MS).

Objectives: To provide real-world evidence of cladribine's effectiveness and safety in people with MS (pwMS). *Methods*: A retrospective observational multi-center, multi-national study of pwMS who were started on cladribine tablets in ten centers from five European countries.

Results: We identified 320 pwMS treated with cladribine tablets. The most common comorbidities were arterial hypertension and depression. Three patients had resolved hepatitis B infection, while eight had positive Quantiferon test prior to cladribine commencement. There were six pwMS who had malignant diseases, but all were non-active. During year 1, 91.6% pwMS did not have EDSS worsening, 86.9% were relapse-free and 72.9% did not have MRI activity. During the second year, 90.2% did not experience EDSS worsening, 86.5% were relapse-free and 75.5% did not have MRI activity. NEDA-3 was present in 58.0% pwMS in year 1 and in 54.2% in year 2. In a multivariable logistic regression model age positively predicted NEDA-3 in year 1. The most common adverse events were infections and skin-related adverse events. Lymphopenia was noted in 54.7% of pwMS at month 2 and in 35.0% at month 6. Two pwMS had a newly discovered malignant disease, one breast cancer, and one melanoma, during the first year of treatment.

Conclusion: Our real-world data on the effectiveness and safety of cladribine tablets are comparable to the pivotal study and other real-world data with no new safety signals.

* Corresponding author at: Department of Neurology, University Hospital Center Zagreb, Kišpatićeva 12, HR-10000 Zagreb, Croatia. *E-mail address*: mhabek@mef.hr (M. Habek).

https://doi.org/10.1016/j.jneuroim.2023.578164

Received 9 May 2023; Received in revised form 29 June 2023; Accepted 25 July 2023 Available online 27 July 2023 0165-5728/© 2023 Elsevier B.V. All rights reserved.

^b School of Medicine, University of Zagreb, Zagreb, Croatia

^e Department of Neurology, University of Szeged, Szeged, Hungary

^f Faculty of Medicine, University of Belgrade, Belgrade, Serbia

^g Clinic of Neurology, University Clinical Center of Serbia, Belgrade, Serbia

1. Introduction

Cladribine is an oral disease-modifying drug authorized by the European Medicine Agency for the treatment of highly active relapsing multiple sclerosis (MS) in 2017 (European Medicines Agency, 2022). The approved dosing regimen is 3.5 mg per kilogram of body weight delivered over two consecutive years, with two treatment weeks separated by one month each year (European Medicines Agency, 2022; Giovannoni et al., 2010). Cladribine is a synthetic purine analog that interferes with DNA synthesis, providing semi-selective immune reconstitution that accounts for prolonged treatment effects after a short treatment dose (Baker et al., 2019). It targets lymphocytes, as highly active proliferating cells, which depend on two key enzymes involved in adenosine metabolism, the activating deoxycytidine kinase (DCK) and the inhibitory cytoplasmic 5' nucleotidases (5NT) (Baker et al., 2019). The semi-selectivity of cladribine can be explained by the relative expression of the DCK to 5NT ratio in different lymphocyte subsets (Baker et al., 2019). The highest expression of DCK with low 5NT is found in B cell subsets, followed by CD4 T subsets, while CD8 T subsets, NK cells, and plasma cells have a lower DCK to 5NT ratio (Baker et al., 2019). Neutrophils and monocytes show high 5NT expression and low DCK, so the absolute numbers of monocytes and neutrophils are maintained following cladribine treatment (Baker et al., 2019). The therapeutic efficacy is thought to be caused by a marked and long-term depletion of memory B cell subsets, coupled with a less pronounced, but likewise long-term, depletion of CD4 T subsets (Baker et al., 2019). The population of CD4 T regulatory cells, CD8 T suppressor cells, and regulatory B cells recover rapidly, so repopulating pathogenic cells reemerge into a regulatory environment, which appears to lead to the re-establishment of immune tolerance (Baker et al., 2019). A limited influence on cells of the innate immune system and modest effects on CD8 and plasma cells contributes to cladribine's safety as these cells allow for immediate and durable protection from infection (Baker et al., 2019).

The efficacy and safety of oral cladribine in people with relapsing multiple sclerosis (pwMS) were investigated in the CLARITY Phase III study, followed by the 2-year CLARITY Extension study (Giovannoni et al., 2010; Giovannoni et al., 2018). Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and the accumulation of new T2 hyperintense lesions on brain MRI compared to placebo (Giovannoni et al., 2010). Although randomized controlled trials provide the highest level of a drug's efficacy and safety, they are fraught with several limitations. Firstly, the drug is investigated on a highly selected group of patients that may not reflect the characteristic of pwMS encountered in everyday clinical practice. Secondly, the drug is studied on a small number of pwMS with a limited follow-up which may not reveal the true extent of the drug's long-term efficacy which is especially important with an immune reconstitution type of MS treatment where the durable effect of the drug on disease activity is expected. In recent years, long-term data from Italian pwMS who participated in cladribine tablets randomized clinical trials, along with real-world data cohorts from Germany, Finland, Australia, Italy, and Canada, have been published, which is necessary for the understanding of cladribine's role in a real-world clinical setting (Patti et al., 2020; Pfeuffer et al., 2022; Rauma et al., 2022; Lizak et al., 2021; Bose et al., 2021; Petracca et al., 2022). In this study, we report real-world data on cladribine use in five southeast European countries - Croatia, Slovenia, Serbia, Montenegro, and Hungary.

2. Patients and methods

2.1. Patients

This was a retrospective observational multi-center study. The study population consisted of pwMS who were started on cladribine tablets in ten centers from five European countries: University Hospital Center Zagreb, University Hospital Center Sisters of Charity, University Hospital Dubrava, General Hospital Virovitica, National Memorial Hospital "dr. Juraj Njavro" Vukovar, and General Hospital Bjelovar in Croatia; University Medical Centre Ljubljana in Slovenia, University Hospital Szeged in Hungary, University Clinical Centre of Serbia in Serbia, and Clinical Center of Montenegro in Montenegro. The inclusion criteria were: 1) start of treatment with cladribine tablets after the reimbursement approval in participating countries in the period from July 2018 to April 2022, 2) complete at least a 1st-year course of treatment (a total dose of 1.75 mg per kg body weight over the two months), 3) relapsing-remitting multiple sclerosis and 4) minimal data set consisting of the number of relapses and EDSS available for the year prior of treatment start. Cladribine tablets were administered according to the summary of product characteristics in a dose of 3.5 mg/kg over two years.

2.2. Methods

Electronic data records were analyzed for all participants. Demographic and disease-related data such as age, sex, disease duration, and previous disease-modifying therapy (DMT) exposure were collected. Data on clinical and radiological activity 12 months prior to cladribine initiation was collected with a follow-up of up to 24 months. Baseline EDSS (Expanded Disability Status Scale) was defined as the last recorded EDSS within one year before treatment initiation and the baseline number of relapses and MRI activity was defined as the number of relapses and MRI activity during that year. Clinical disease activity was defined as a presence of a relapse defined as an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: Symptoms must persist for >24 h and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications); Symptoms should be preceded by neurological stability for at least 30 days; Symptoms should be accompanied by new objective neurological worsening determined with a timely EDSS/ Functional Systems Score (FSS) assessment. Active MRI lesions were defined as the presence of new or enlarging and/or Gd + lesions on the follow-up MRI. NEDA-3 (no relapses, no EDSS progression, and no active lesions on brain MRI) was assessed at month 12 and month 24. All the data on disease activity was analyzed separately for the first (baseline to 12 months) and second (13-24 months) year of follow-up as the patients started cladribine treatment at various time points.

Ethical approval from the Ethical Committee of the University Hospital Center Zagreb was obtained for the study. Since this was a retrospective study, patient consent was not required according to the local legislation of each center.

2.3. Objectives

The primary objective of this study was to identify how many pwMS treated with cladribine did not have signs of clinical or radiological activity in years 1 and 2 of follow-up.

Secondary objectives were: (1) to identify how many patients with pwMS treated with cladribine achieved NEDA-3 at month 12 and month 24, (2) to identify how many pwMS treated with cladribine were relapse-free during the entire follow-up, (3) to identify predictors of achieving NEDA-3, (4) to identify predictors of being relapse-free, and (5) to evaluate the safety of the treatment.

2.4. Statistical analysis

Statistical analysis was performed with the software IBM SPSS v25. The Kolmogorov-Smirnov test was applied to test whether the data have a normal distribution. Differences between repetitive measures were determined with the Wilcoxon signed ranks test. Univariable logistic regression analysis was used to determine which variables were statistical predictors of achieving NEDA-3 at 12 and 24 months. Variables that

Table 1

Demographic and clinical characteristics of the study cohort.

	n = 320
Age years (SD)	41.6 ± 10.6
Gender n (%) female	241 (75.3)
Disease duration years (min-max)	6.63 (0.12-41.0)
EDSS median (min-max)	3.0 (0-7.5)
Previous DMT n (%)	
No	85 (26.6)
Yes	235 (74.4)
MET*	189 (59.1)
Any interferon	91 (48.1)
Glatiramer acetate	66 (34.9)
Teriflunomide	35 (18.5)
Dimethyl fumarate	50 (26.5)
Azathioprine	1 (0.5)
HET*	46 (14.4)
Alemtuzumab	13 (28.3)
Natalizumab	13 (28.3)
Fingolimod	23 (50.0)
Ozanimod	2 (4.3)
Ocrelizumab	1 (2.2)
Mitoxantrone	2 (4.3)
Daclizumab	2 (4.3)
Number of previous DMTs n (%)	
1	147 (62.6)
2	64 (27.2)
3	23 (9.8)
4	1 (0.4)
Relapses at baseline ^a n (%)	n = 317
No	50 (15.8)
1	146 (46.1)
2	95 (30.0)
3	25 (7.9)
4	1 (0.3)
Active lesions on MRI at baseline ^a n (%)	n = 296
No	106 (35.8)
1	46 (15.5)
2	18 (6.1)
≥ 3	126 (42.6)
Gd + lesions on MRI at baseline ^a n (%)	n = 245
No	149 (60.8)
1	54 (22.0)
2	14 (5.7)
≥ 3	28 (11.4)

EDSS-expanded disability status scale. DMT-disease modifying therapies. METmoderate efficacy therapies. HET-high efficacy therapies. Gd-gadolinium.

^{*} Single pwMS could have been on several previous DMTs, therefore the numbers cannot be summed up.

^a During 12 months prior to starting cladribine tablets.

achieved statistical significance (p < 0.20) were included in the multivariable logistic regression model. Survival analysis was performed in the form of Cox regression model to define which variables are statistically significant predictors of relapse occurrence. Statistical significance was set at 0.05.

3. Results

3.1. Baseline characteristics of the studied cohort

We identified 320 pwMS treated with cladribine tablets. Demographic and clinical characteristics are presented in Table 1. There were 75.3% (241) females, the mean age was 41.6 ± 10.6 years and the median disease duration was 6.63 (0.12–41.0) years. The median EDSS at baseline was 3.0 (0–7.5) and 26.6% were treatment naïve prior to cladribine commencement. Of the 74.4% previously treated with DMT, 59.1% received drugs with moderate efficacy, while 14.4% were treated with high efficacy therapies. Details on DMTs used and the number of previous DMTs used are provided in Table 1. In most instances, the switch to cladribine tablets was made due to clinical or MRI disease activity. Only pwMS who were switched from natalizumab (positive JCV titers), daclizumab (drug withdrawal), ocrelizumab (adverse event), or mitoxantrone (cardiac safety), were switched due to safety reasons. In the 12 months prior to cladribine initiation, 84.2% experienced relapses, and 64.2% had active lesions on brain MRI. The mean annualized relapse rate (ARR) at baseline was 1.31 ± 0.84 .

Data on comorbidities were available for 97 pwMS and are presented in the supplementary table (Table S1). The most common comorbidities were arterial hypertension and depression. Three patients had resolved hepatitis B infection, while eight had positive Quantiferon test prior to cladribine commencement. There were six pwMS who had malignant diseases, but all were non-active.

3.2. 12-month follow-up

Data for the 12-month follow-up was available for 245 pwMS (Fig. 1). After 12 months 91.6% did not have EDSS worsening, 86.9% were relapse-free and 72.9% did not have MRI activity. The mean ARR at month 12 was 0.13 \pm 0.35. NEDA-3 was present in 58.0% pwMS. According to univariable logistic regression analysis, older age was a predictor of achieving NEDA-3 at 12 months (exp(B) 1.066, 95%CI 1.033–1.101, p < 0.001) (Table 2). In a multivariable logistic regression model older age positively predicted NEDA-3 at 12 months of follow-up and EDSS >3 at the baseline was a statistically significant negative predictor of NEDA-3 at 12 months.

3.3. 24-month follow-up

Data for the 24-month follow-up was available for 129 pwMS (Fig. 1). At month 24 (during the second year of follow-up), 90.2% did not experience EDSS worsening, 86.5% were relapse-free, and 75.5% did not have MRI activity. The mean ARR at month 24 was 0.13 ± 0.34 . NEDA-3 was present in 54.2% at month 24 (months 13 to 24). According to univariable logistic regression analysis, at 24-months older age (exp (B) 1.047, 95%CI 1.004–1.091, p = 0.031) and longer disease duration (exp(B) 1.075, 95%CI 1.006–1.149, p = 0.032) were predictors of NEDA-3 (Table 2). In the multivariable analysis, those values were not statistically significant. Age was also a predictor of being relapse-free during both years of follow-up according to Cox regression analysis (exp(B) 0.950, 95% CI 0.921–0.979, p = 0.001).

3.4. Adverse events and lymphopenia

Data regarding adverse events were available for 114 pwMS in the first year of treatment and 86 pwMS in the second year of treatment (Table 3). The most common adverse events were infections, mainly urinary tract infections, and oral herpes simplex. The second most common were skin adverse events such as rash and hair loss. Two pwMS had a newly discovered malignant disease, one breast cancer, and one melanoma, during the first year of treatment.

Lymphocyte levels were available for 261 (81.6%) pwMS prior to starting cladribine, 181 (56.6%) two months after, and 183 (57.2%) six months after cladribine initiation. 253 pwMS had normal lymphocyte levels prior to starting cladribine, while five had grade 1 lymphopenia and 3 grade 2 lymphopenia. Two months after cladribine initiation 45.3% had normal lymphocyte levels, 22.7% had grade 1 lymphopenia, and 25.4% and 6.6% had lymphopenia grade 2 and 3, respectively. At month 6 normal lymphocyte levels were observed in 65%, grade 1 lymphopenia in 19.1% while 12.6% and 3.3% of pwMS had grade 2 and 3 lymphopenia, respectively. Cases of grade 4 lymphopenia were not recorded during the follow-up period. Compared to levels before cladribine start, levels of lymphocytes were statistically significantly lower at month 2 (1.660 (0.790–4.600)/ μ L \pm vs. 0.952 (0.210–3.500)/ μ L, p < 0.001) and month 6 (1.630 (0.790–4.600)/ μ L vs. 1.100 (0.400–3.080)/ μ L, p < 0.001) when compared to levels before cladribine start. As well, levels of lymphocytes were significantly lower at month 2 when compared to month 6 levels (0.925 (0.210-3.500)/µL vs. 1.090



Fig. 1. Disease activity in the first (at 12 months) and second year of follow-up (months 13 to 24). EDSS-expanded disability status scale. NEDA-3-no evidence of disease activity (absence of relapses, EDSS progression, and MRI activity).

 $(0.400-3.080)/\mu L, p < 0.001)$ (Fig. 2).

4. Discussion

This study provides results on the use of cladribine tablets in a realworld population of pwMS in five European countries. The initial efficacy and safety data on cladribine tablets in pwMS was provided by the randomized placebo-controlled CLARITY study (Giovannoni et al., 2010). In the 3.5 mg/kg dose of the cladribine arm there were 68.8% females with a mean age of 37.9 years, mean disease duration of 7.9 years, and mean EDSS score of 2.8. In the current study, the cohort was older (mean age 41.6 years), with a higher female-to-male ratio (75.3% females), shorter disease duration (median 6.63) years, and a similar EDSS (median 3.0). In our study, most of the patients (74.4%) have been previously treated with DMT while in the CLARITY study, only 26.1% of patients were previously treated.

In the CLARITY study, 79.7% of the patients treated with cladribine did not experience relapses after 96 weeks (Giovannoni et al., 2010). A recently published nationwide registry study in Finland demonstrated that 83.6% remained relapse-free after 12 months of follow-up (Rauma et al., 2022). This is in line with the results of our study where 86.9% and 86.5% of pwMS did not experience relapses in the first and second year, respectively, after cladribine treatment initiation. A lower rate of relapse-free patients, 65% two years after cladribine treatment, was reported in an Australian cohort of patients (Lizak et al., 2021). However, a limitation of that report is that due to the withdrawal of the commercially available cladribine 87 out of 90 patients only received the first year of treatment.

It has been demonstrated that cladribine treatment causes a substantial decrease in MRI activity as well. In the CLARITY trial cladribine treatment led to a relative reduction of 73.4% in T2 active lesions on brain MRI compared to placebo (Giovannoni et al., 2010). A significant reduction in the occurrence of new or enlarging T2-hyperintense MRI lesions was found in a real-world study from two tertiary centers in Germany, as well (Pfeuffer et al., 2022). In the current study, 72.9% and 75.5% of pwMS did not have active lesions on MRI at 12 and 24 months, respectively, compared to 35.8% on baseline.

EDSS worsening was rare in our cohort and was present in 8.4% and 9.8% of patients at month 12 and month 24, respectively. This was consistent with the results from the CLARITY study as well as other real-world studies. In the CLARITY trial 3-month sustained EDSS progression

was present in 14.3% of patients 96 weeks after cladribine treatment (Giovannoni et al., 2010). In a real-world study from Italy, EDSS worsening was recorded in 12.7% of patients after a median follow-up of 22 months (Petracca et al., 2022). In the German cohort, EDSS remained stable in the majority of patients after 36 months of follow-up (Pfeuffer et al., 2022).

NEDA-3 was achieved by 58.0% and 54.2% of pwMS in our cohort in the first and second year of treatment, respectively. These results are in the range of those recorded in real-world and phase III studies. In the Italian real-world cohort NEDA-3 was observed in 64% of patients after a median of 22 months while in a post-hoc analysis of the CLARITY study NEDA-3 was present in 44% of patients (Petracca et al., 2022; Giovannoni et al., 2011).

In the current cohort we analyzed possible predictors of future disease activity after cladribine treatment. Age was a predictor of being relapse free during both years of follow-up (exp(B) 0.947, 95% CI 0,919–0.976, p < 0.001). Similar results have been found in a single-center real-world study in Canada where older age at treatment was associated.

with lower risk of developing a new clinical relapse (Bose et al., 2021). Age being a predictor of being relapse-free is not surprising as it has been demonstrated that relapses are age dependent in pwMS. In a retrospective study with a mean follow-up of 20.6 years the relapse rate started declining in patients aged over 40 and decreased by 17% every 5 years (Tremlett et al., 2008). As our cohort had a mean age of 41.6 years this may have been reflected in relapse occurrence. As well, age was a predictor of NEDA-3 in our cohort. Univariable logistic regression analysis revealed age to be a predictor of achieving NEDA-3 at 12 months (exp(B) 1.066, 95%CI 1.033–1.101, p < 0.001). At 24-months age (exp(B) 1.047, 95%CI 1.004–1.091, p = 0.031) and disease duration (exp(B) 1.075, 95%CI 1.006–1.149, p = 0.032) were predictors of NEDA-3. In a multivariable logistic regression model age positively predicted NEDA-3 and EDSS>3 at baseline negatively predicted NEDA-3 at 12 months of follow-up. In contrast, the analysis of the Italian and German real-world cohorts did not find age to be a predictor of either NEDA-3 or relapses at the end of the follow-up (Pfeuffer et al., 2022; Petracca et al., 2022). As well, EDSS at baseline was not associated with the time to loss of NEDA-3 in the German cohort (Pfeuffer et al., 2022). We did not find an effect of previous DMT exposure on future relapses or NEDA-3. This is consistent with findings from the post hoc analysis of the CLARITY trial as well as real-world data where previous DMT

Table 2

Results of the univariable and multivariable logistic regression model for predicting NEDA-3 at month 12 (during the first year of follow-up), and month 24 (13–24 months of follow-up); and results of the Cox regression analysis for the relapse occurrence during the entire follow up.

ReppackpackpackpackpackpackpackpackNUM-11.061.031-1100.1710.0200.0200.030-1.010.0300.030-1.01Number of carbon1.0280.065-1.0720.1010.030-1.010.030-1.010.030-1.010.030-1.010.030-1.010.030-1.010.030-1.010.030-1.010.030-1.010.030-1.010.030-1.010.030-1.010.030-1.010.030-1.010.030-0.01<		Univariable	logistic regression		Multivariable logistic regression				
NetworkNetworkNetworkNetworkNetworkNetworkNetworkSa0.0600.031-10.00.0700.0700.030-10.200.0100.033-10.200.010Desce duration 5-years0.940.541-12.000.850.850.850.850.85EDSS habadina0.0210.351-12.000.81<		Exp (B)	95% CI for Exp (B)	p value	Exp (B)	95% CI for Exp (B)	p value		
Age1.0661.033-1.194.0401.0411.0410.4040.4040.4060.406Sex1.2120.951-1.2600.9510.9510.9510.9510.951EDSS handbalae0.4040.790-1.1200.1310.4030.790-1.2000.9510.951EDSS handbalae0.4030.551-1.1200.1310.4030.790-1.2000.951 </td <td>NEDA-3 at month 12</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	NEDA-3 at month 12								
seri0.0090.012-1.000.1470.0470.306.07210.194Desse duration -5 years0.940.554 -1.760.550.55ESS ob basilier0.940.554 -1.760.540.55EDS a basilier0.630.351 -1.120.450.255EDS a basilier in year prior to baseline0.430.235 -1.120.260.255Reinger in year prior to baseline1.480.205 -3.120.261.480.26Active lesions of MR to baseline0.2350.261.480.261.481.48Previous DMT0.3550.215 -4.040.261.48 <td>Age</td> <td>1.066</td> <td>1.033-1.101</td> <td>< 0.001</td> <td>1.079</td> <td>1.041-1.119</td> <td>< 0.001</td>	Age	1.066	1.033-1.101	< 0.001	1.079	1.041-1.119	< 0.001		
Descend quantion10280.9840.9670.1920.1930.953.1.0360.954.1.7800.954Descend quantion Sparsen0.9400.739-1.1250.5430.740 <td< td=""><td>Sex^a</td><td>0.609</td><td>0312-1.190</td><td>0.147</td><td>0.624</td><td>0.306-1.271</td><td>0.194</td></td<>	Sex ^a	0.609	0312-1.190	0.147	0.624	0.306-1.271	0.194		
Descendention 5-years0.9940.574.7660.985DSNs hashen0.6940.799-1.1250.190.4030.205-0.710.008DSNs hashen0.6290.351-1.1260.190.4030.205-0.710.008Rahper in year prior to bashine0.8260.294.1.1500.2030.2050.2050.205Schwart Mill at baseline0.8260.221-3.4000.2020.2030.2050.2050.205230.8260.221-3.4000.2020.5860.2050.2050.2050.205Pervisus DMT0.8260.221-3.4000.5860.2050.2050.2050.2050.205Pervisus DMT0.8270.212-3.4000.205 <td>Disease duration</td> <td>1.028</td> <td>0.986-1.072</td> <td>0.192</td> <td>1.001</td> <td>0.953-1.053</td> <td>0.954</td>	Disease duration	1.028	0.986-1.072	0.192	1.001	0.953-1.053	0.954		
ENS of onserine0.4840.799-1.1250.5430.4030.205-0.7910.003Number of relayses in year prior to baseline0.8250.592-1.1500.2660.205-0.7910.005Relayse in year prior to baseline0.4240.706-3.1210.2640.205-0.7910.205Active leason on MBI at baseline0.8760.201-3.4000.8490.201-0.7920.201-0.79220.8760.201-3.4000.8490.201-0.7920.201-0.7920.201-0.7927 per of proving DMT0.7860.391-1.5490.4750.7920.7920.7920.792Type of proving DMTUP OF	Disease duration >5 years	0.994	0.554-1.786	0.985					
ENS on baseline0.630.31-1260.1010.4030.205-07.010.005Relape in year prior to baseline0.8200.292-1.3400.202 <td>EDSS on baseline</td> <td>0.948</td> <td>0.799-1.125</td> <td>0.543</td> <td></td> <td></td> <td></td>	EDSS on baseline	0.948	0.799-1.125	0.543					
Number of relapse in year prior to baseline1.8490.5921.8480.706-3.1210.2011.8481.8480.706-3.121Active lesions on MRI at baseline'0.5380.201-3.4000.8491.8480.84920.8500.212-3.4000.8491.8481.8481.84820.8500.212-3.4000.8491.8481.8481.848Previous DMT0.8600.416-1.6420.8601.8481.8481.848Previous DMT0.5720.212-1.3110.6161.8481.8481.848Previous DMT0.5720.212-1.3110.6611.8481.6180.844-1.0810.198Sex*0.4741.040-1.0910.6141.6180.644-1.230.1981.8580.5641.8580.564-1.1230.5781.8580.564-1.1230.5781.8580.564-1.1230.5781.8580.564-1.1230.5781.8580.564-1.1230.5781.8580.564-1.1230.5781.8580.564-1.1230.5781.8580.564-1.1230.5781.5881.5880.564-1.1230.5781.5885.5881.5880.564-1.1230.5641.5881.5881.5880.564-1.1230.5641.588<	EDSS > 3 on baseline	0.629	0.351 - 1.126	0.119	0.403	0.205-0.791	0.008		
Relay point on baseline citror lesson on MRI at baseline'0,7630,2630.26310,5730,221-3,4600,8740,26220,8750,221-3,4600,8641.56220,8750,221-3,4600,8641.56220,7140,8560.5661.562Previous DMT0,7140,8750.212-1110.561Previous DMT0,770,212-1,3110,611.0310,964-1,0810,19MEMO0,780,3110,4132,1110,310,964-1,0210,31Disase duration1.080,4130,4130,4321.0410,964-1,1230,31Disase duration0.9500,4020,571.561.561.561.561.56Disase duration0.9700,432,2170,571.561	Number of relapses in year prior to baseline	0.825	0.592-1.150	0.256					
Active elsams on MRI at baseline*Real10.5380.208-1.394.0.20120.8750.221.3.460.0.84920.8750.221.3.460.0.84920.8760.310-1.642.0.521Previous DMT0.740.321.0.321Type of previous DMT0.780.391-1.549.0.475HET0.7780.391-1.549.0.475HET0.7780.391-1.549.0.6311.031Previous DMT0.7810.041.0.6311.031BERS1.0841.004-1.0910.6321.0410.984-1.081Sec*0.1880.413.2.5110.6321.0410.964-1.1230.370Disease duration 5 years0.2800.959.5.4200.6301.8430.507EDSS >0 baseline0.9700.432.2.1740.4320.3011.5451.845Number of relapses in year prior to baseline0.9100.226.3.7300.6371.451.4520.9700.535.5.3730.9241.451.451.451.4520.9550.354.2.5740.9241.451.451.451.4520.9500.354.2.5730.6361.451.451.451.4520.9700.363.4.5.7970.631.451.451.451.4520.9700.394.5.7970.631.451.451.451.4520.9700.394.5.7970.631.451.451.451.4	Relapse in year prior to baseline	1,484	0.706-3.121	0.298					
10.3080.2043940.20220.4750.2214360.484>30.7400.5860.484>30.7140.5210.586Previous DMT*0.7140.7210.2211310.475HET0.7780.3911540.4750.781HET0.7810.4121310.6910.984-1.0810.191Step 11.0180.4130.6921.0180.9411230.301Dissae duration1.0180.4130.6100.5071.0180.5071.0180.507Dissae duration2.2800.95954.0100.6201.410.9641.230.3011.52Dissae duration0.7900.44321010.5071.52 <t< td=""><td>Active lesions on MRI at baseline^b</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Active lesions on MRI at baseline ^b								
20.850.212-3.600.84430.8200.416-1.6420.586Previous DMT0.3200.221-3.110.475HET0.780.391-1.5490.475HET0.780.391-1.5490.475HET0.780.391-1.5490.475HET0.780.391-1.5490.475HET0.169	1	0.538	0.208-1.394	0.202					
330.6260.416-1.6420.366Previous DMT	2	0.875	0.221-3.460	0.849					
Previous DNT0.7140.321Type of previous DNT0.7780.391-1.5490.475HET0.7780.221-1.3110.475HET0.0780.221-1.3110.645HET0.0780.221-1.3110.69Sec*1.0180.413-2.5110.661Disease duration1.0751.006-1.1490.0321.0410.696+1.1230.370Disease duration0.9700.432-2.1700.6211.0181.0181.0181.018Disease duration0.9700.432-1.7700.6411.0181.0181.0181.0181.018Disease duration0.9700.432-1.7700.6411.018	>3	0.826	0 416-1 642	0.586					
Type of previous DMT*NoteMET0.391-1.5400.475MET0.5270.212-1.3110.469NEMA0.5270.212-1.3110.690NEMA1.0180.413-2.5110.6920.612Sec*1.0181.041-0.910.6020.6120.612Disease duration >5 years2.2600.6400.6271.0150.614-1.0230.301Disease duration >5 years0.9200.740-1.0100.5671.015	Previous DMT	0.714		0.321					
MT0.7780.391-1.5490.475HET0.5270.212-1.3110.169MEDA-3 tronth 24Age1.0471.004-1.0910.0310310.964-1.0810.178Sex*1.0180.412.5.2110.069	Type of previous DMT ^c	*** = *							
HTT0.100 0.212-1310.169HET0.212-1310.169NEDA:3 trooth 241.004-1.0910.0311.0310.984-1.0810.198Sex*1.0180.413-2.5110.0601.0410.964-1.1230.191Disease duration -5 years2.2800.595-5.4200.0621.0410.964-1.1230.171Disease duration -5 years0.9700.432-2.1770.9411.111.111.111.11EDSS on baseline0.9700.432-2.1770.9411.11 <t< td=""><td>MFT</td><td>0 778</td><td>0 391_1 549</td><td>0.475</td><td></td><td></td><td></td></t<>	MFT	0 778	0 391_1 549	0.475					
Nome of the origonal set of the set of	HFT	0.527	0.212_1.311	0.169					
Age1.0471.004-1.0910.0311.0310.984-1.0810.198Sec'1.0180.413-2.5110.969Disease duration1.0751.006-1.1490.0321.0410.964-1.1230.307Disease duration >5 years2.2800.959-5.4200.062EDSS on baseline0.9700.432-2.1770.941	NEDA-3 at month 24	0.02/	0.212 1.011	0.109					
late base	Age	1 047	1 004-1 091	0.031	1.031	0 984-1 081	0 1 9 8		
Decay Descent duration10.050.0020.020.0620.062Discase duration >5 years2.2800.959-5.4200.0620.620.970EDSS on baseline0.9700.432-2.1770.9410.5070.941EDSS on baseline0.9700.432-2.1770.9410.7700.782Relapse in year prior to baseline0.9400.236-3.7390.930	Sev ^a	1.047	0.413-2.511	0.051	1.001	0.904-1.001	0.190		
Dataset unitation > 5 years 2.00 1.003 1.0042 1.0012 1.0012 0.002 1.001 0.002 0.001 0.002 0.001 0.002 0.001 <	Disease duration	1.018	1 006 1 140	0.909	1.041	0.064 1.123	0.307		
Datase 2.200 0.797 0.740-1.160 0.507 EDSS on baseline 0.970 0.432-2177 0.941 EDSS on baseline 0.970 0.432-2177 0.941 Number of relapses in year prior to baseline 0.940 0.236-3.739 0.930 Active lesions on MRI at baseline* 0.940 0.236-3.739 0.930 Active lesions on MRI at baseline* 0.940 0.236-3.739 0.930 Active lesions on MRI at baseline* 0.940 0.236-3.739 0.930 Active lesions on MRI at baseline* 0.940 0.482 0.930 Active lesions on MRI at baseline* 0.940 0.927 T 1 0.650 0.542-5.74 0.927 T Previous DMT 2.411 0.855-6.797 0.096 1.885 0.614-5.601 0.273 Type of previous DMT 1.158 1.065-9.361 0.038 1.067 0.663 1.041 1.02 Berge coursence 1.319 0.380-1.57 0.663 1.041 1.02 1.020 1.020	Disease duration >5 years	2 280	0.050 5.420	0.052	1.041	0.904-1.125	0.307		
LDS of lobeline0.5270.7400.547DSS 3 of baseline0.6110.432-2.1720.941Number of relapses in year prior to baseline0.8110.433-1.3610.423Relapse in year prior to baseline0.9000.300-Active lesions on MR1 at baseline ¹⁰ 0.5360.537.5310.92423.640.9170.152-5.5310.92423.60.9550.354-2.5740.927-Previous DMT0.5800.354-2.5740.927-Type of previous DMT0.5800.5630.663-HET1.160.380-4.5710.663-Type of previous DMT0.380-4.5710.663-HET1.190.380-4.5710.663-Marcinable CoursenseName previous On analysisNative previous on analysisNative previous on analysisMET0.9470.919-0.9760.0010.9500.921-0.9790.01Sex ⁴ 0.9470.919-0.9760.0100.9500.921-0.9790.01Sex ⁴ 0.9820.937-1.0290.4391.571.581.581.58Disease duration >5 years0.9860.575-1.4490.56-1.2710.874-1.8500.210Disease duration >5 years0.6860.575-1.4490.561.55Disease duration >5 years0.5610.952-1.9990.904Relapse in year prior to baseline0.3600.374-	EDCC on baseline	2.200	0.740 1 160	0.002					
LDS 30 in laseline0.5900.432-1.170.5910.428Number of relapses in year prior to baseline0.5000.230-3.7390.3300.330Active lesions on MR at baseline*3.6670.636-21.1470.1461.4220.9170.152-5.5310.9241.421.4220.9170.354-2.5740.9271.420.4120.9500.354-2.5740.9271.420.43Previous DMT2.4110.855-6.7970.9661.8850.614-5.6010.273Type of previous DMT*1.1390.380-4.5770.6631.411.510.424HET1.3190.380-4.5770.6631.41NNNMetrational Constraints95% (T for MR9 % N for for MRP valueRespondent Constraints1.6995% (T for MRP valueRespondent Constraints95% (T for MR9.500.921-0.9790.901Sex*0.9710.390-1.3670.3261.411.510.901Disease duration0.9820.397-1.0290.4391.411.511.41Disease duration >5 years0.9520.952-1.9490.8611.211.411.511.41Disease duration >5 years0.5630.575-1.4440.5610.2441.411.511.41EDSS on baseline0.5630.575-1.4440.5461.511.411.511.41Disease duration >5 years0.5620.575-1.4440.5261.511	EDSS off Daseline	0.927	0.740-1.100	0.307					
Number of relayes in year prior to baseline0.810.4300.423Relaye in year prior to baseline0.9000.236-37390.930Active lesions on MRI at baseline ¹⁶ 0.6360.636-21.1470.14620.9170.152-5.5310.924 \geq 30.9550.334-2.5740.927Previous DMT2.41100.855-6.7970.6630.614-5.6010.273Type of previous DMT ⁻ 0.1520.3810.0550.614-5.6010.273HET3.1581.065-9.3610.0630.6140.8730.614HET1.3190.380-4.5770.6630.6140.9730.914HET0.3900.390-1.570.6310.9500.921-0.9790.914Relayes occurrenceHR9.640 for HRHR95% Cl for HR1.91Sex ² 0.9470.919-0.976<0.010	ED35 >5 oil Dasellile	0.970	0.492 1.261	0.941					
Relape in year piton baseline0.59400.59500.595Active lesions on MRI at baseline3.6670.636-21.1470.14620.9170.152-5.5310.92420.9550.334-2.5740.927Previous DMT2.4110.855-6.7970.9261ype of previous DMT [*]	Relapse in year prior to baseline	0.811	0.226 2.720	0.428					
Active resolution interface baseline 1 3.667 0.536-21.147 0.146 2 0.917 0.152-5.531 0.924 ≥3 0.955 0.955 0.927 Previous DMT 2.411 0.855-6.77 0.966 1.885 0.614-5.601 0.273 Type of previous DMT* MET 1.319 0.360-4.577 0.663 .	Active losions on MBL at baseline	0.940	0.230-3.739	0.930					
1 3.667 0.630-2.1147 0.146 2 0.917 0.152-5.513 0.927 ≥3 0.555 0.354.2.574 0.927 Previous DMT° 0.096 1.885 0.614-5.601 0.273 Type of previous DMT° 0.058 0.614-5.601 0.273 HET 3.158 1.065-9.361 0.038 0.633 HET 1.319 0.380 -4.577 0.663 - Reapse occurrence HR 95% CI for HR P value HR 95% CI for HR P value Reapse occurrence - </td <td>Active resions on wiki at baseline</td> <td>2667</td> <td>0.626.21.147</td> <td>0.146</td> <td></td> <td></td> <td></td>	Active resions on wiki at baseline	2667	0.626.21.147	0.146					
2 0.917 0.152-3.31 0.924 ≥3 0.955 0.5744 0.927 Previous DMT 2.411 0.855-6.797 0.096 1.885 0.614-5.601 0.273 Type of previous DMT [*]	1	0.017	0.150 5 521	0.140					
23 0.953 0.354–2.574 0.927 Previous DMT 2.411 0.855–6.797 0.966 1.885 0.614–5.601 0.273 Type of previous DMT*	2	0.917	0.152-5.531	0.924					
Previous DM12.4110.853-0.790.0961.8650.6145.010.273Type of previous DMT3.1581.065-9.3610.038MET3.1581.065-9.3610.038 <td< td=""><td>≥o Durai ana DMT</td><td>0.955</td><td>0.354-2.574</td><td>0.927</td><td>1.005</td><td>0 (14 5 (01</td><td>0.070</td></td<>	≥o Durai ana DMT	0.955	0.354-2.574	0.927	1.005	0 (14 5 (01	0.070		
Here 3.158 1.065-9.361 0.038 HET 1.319 0.380-4.577 0.663 HET HR 95% C1 for HR Palae Fersonanalysis HR 95% C1 for HR Palae Palae Palae Relapse occurrence - - - - Sex ⁴ 0.947 0.919-0.976 0.901 0.921-0.979 0.001 Sex ⁴ 0.947 0.919-0.976 -	Trans of averaging DMT	2.411	0.855-0.797	0.096	1.885	0.014-5.001	0.273		
ME13.1881.0630.038HET1.3190.380-4.5770.663HETUnivariable Cox regression analysisMultivariable Cox regression analysisNultivariable Cox regression analysisRease occurrenceHR95% CI for HR9 valueHR95% CI for HRP valueReg0.9470.919-0.976 $<$ 00010.9500.921-0.9790.001Sex ⁴ 0.7300.390-1.3670.326 $<$ $<$ $<$ Disease duration0.9820.937-1.0290.439 $<$ $<$ $<$ $<$ Disease duration >5 years0.9870.532-1.8330.986 $<$ $<$ $<$ $<$ $<$ Disease duration >5 years0.9860.799-1.1430.619 $<$ $<$ $<$ $<$ $<$ Disease in year prior to baseline0.8680.385-1.9600.866 $<$ $<$ $<$ $<$ $<$ $<$ $<$ Relapse in year prior to baseline0.8680.385-1.9600.734 $<$ $<$ $<$ $<$ $<$ $<$ $<$ 116.5750.9490.326 $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ 230.5820.3860.326 $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ <td>Type of previous DMT</td> <td>0.150</td> <td>1.005.0.001</td> <td>0.000</td> <td></td> <td></td> <td></td>	Type of previous DMT	0.150	1.005.0.001	0.000					
HE11.5190.3690.663Multivariable ConstraintsMultivariable ConstraintsHR95% CI for HRP valueHR95% CI for HRP valueRelapse occurrence95% CI for HRP valueAge0.9470.919–0.9760.0010.9500.921–0.9790.001Sex*0.9820.390-1.3670.326 </td <td>MEI</td> <td>3.158</td> <td>1.065-9.361</td> <td>0.038</td> <td></td> <td></td> <td></td>	MEI	3.158	1.065-9.361	0.038					
Invariable Cov Fegression analysisMultivariable Cov Fegression analysisMultivariable Cov Fegression analysisIR \mathbb{P} % Cl for HR \mathbb{P} value \mathbb{P} value \mathbb{P} value \mathbb{P} value \mathbb{P} value \mathbb{P} walue \mathbb{P} value <td< td=""><td>HEI</td><td>1.319</td><td>0.380-4.577</td><td>0.663</td><td colspan="5">Multiveriable Coursession englusis</td></td<>	HEI	1.319	0.380-4.577	0.663	Multiveriable Coursession englusis				
RefP ValueP ValueP ValueP ValueP ValueP ValueRelaye ocurrence R 9 S% Cl for RRP ValueAge0.9470.919-0.976<0.0010.9500.921-0.9790.001Sex ^a 0.7300.390-1.3670.326Disease duration >5 years0.9870.532-1.8330.986 </td <td></td> <td>Univariable</td> <td>Cox regression analysis</td> <td>D 1</td> <td>Multivariab</td> <td>le Cox regression analysis</td> <td>D 1</td>		Univariable	Cox regression analysis	D 1	Multivariab	le Cox regression analysis	D 1		
Relative for the set of th	Delemen e environ e e	пк	95% CI 10F HR	P value	пк	95% CI 10F HR	P value		
Age0.9470.919-0.9760.0010.9500.921-0.9790.001Sex*0.7300.390-1.3670.3260.3260.326Disease duration0.9820.937-1.0290.4390.439Disease duration >5 years0.9870.532-1.8330.986 $$	A an	0.047	0.010.0.076	-0.001	0.050	0.021.0.070	0.001		
Sex 0.730 0.390 ^{-1.367} 0.326 Disease duration 0.982 0.937-1.029 0.439 Disease duration >5 years 0.987 0.532-1.833 0.986 EDSS on baseline 0.956 0.799-1.143 0.619 EDSS on baseline 1.058 0.575-1.949 0.856 Number of relapses in year prior to baseline 1.379 0.952-1.999 0.090 1.271 0.874-1.850 0.210 Relapse in year prior to baseline 0.868 0.385-1.960 0.734 1 1.057 0.210 Active lesions on MRI at baseline ^b 1 1.657 0.708-3.876 0.244 1 <t< td=""><td>Age</td><td>0.947</td><td>0.919=0.976</td><td><0.001</td><td>0.950</td><td>0.921-0.979</td><td>0.001</td></t<>	Age	0.947	0.919=0.976	<0.001	0.950	0.921-0.979	0.001		
Disease duration 0.932 0.937-1.029 0.937 Disease duration >5 years 0.987 0.532-1.833 0.986 EDSS on baseline 0.956 0.799-1.143 0.619 EDSS >3 on baseline 1.058 0.575-1.949 0.856 Number of relapses in year prior to baseline 1.379 0.952-1.999 0.090 1.271 0.874-1.850 0.210 Relapse in year prior to baseline 0.868 0.385-1.960 0.734 1.271 0.874-1.850 0.210 Relapse in year prior to baseline ^b 1.657 0.708-3.876 0.244 1.271 0.874-1.850 0.210 2 0.360 0.047-2.758 0.326 1.273 1.271 </td <td>Sex Disease duration</td> <td>0.730</td> <td>0.390-1.367</td> <td>0.326</td> <td></td> <td></td> <td></td>	Sex Disease duration	0.730	0.390-1.367	0.326					
Disease duration >5 years 0.987 0.532-1.833 0.986 EDSS on baseline 0.956 0.799-1.143 0.619 EDSS >3 on baseline 1.058 0.575-1.949 0.856 Number of relapses in year prior to baseline 1.379 0.952-1.999 0.090 1.271 0.874-1.850 0.210 Relapse in year prior to baseline ^b 0.868 0.385-1.960 0.734 0.210 Active lesions on MRI at baseline ^b 1 1.657 0.708-3.876 0.244 1.271 0.874-1.850 0.210 2 0.360 0.047-2.758 0.326 1.271	Disease duration	0.982	0.937-1.029	0.439					
EDSS on baseline 0.950 0.799-1.14.3 0.191 EDSS >3 on baseline 1.058 0.759-1.949 0.856 Number of relapses in year prior to baseline 1.379 0.952-1.999 0.090 1.271 0.874-1.850 0.210 Relapse in year prior to baseline 0.868 0.385-1.960 0.734	Disease duration >5 years	0.987	0.532-1.833	0.986					
LDSS >3 on baseline1.0580.575-1.9490.856Number of relapses in year prior to baseline1.3790.952-1.9990.0901.2710.874-1.8500.210Relapse in year prior to baseline0.8680.385-1.9690.7341.2710.874-1.8500.210Active lesions on MRI at baseline ^b 11.6570.708-3.8760.2441.2711.2711.2711.27120.3600.047-2.7580.3261.2731.2711.2711.2711.2711.2711.271230.6550.308-1.3960.2731.2711	EDSS on baseline	0.956	0.799-1.143	0.619					
Number of relapses in year prior to baseline 1.379 0.952–1.999 0.090 1.271 0.874–1.850 0.210 Relapse in year prior to baseline 0.868 0.385–1.960 0.734 0.734 Active lesions on MRI at baseline ^b 1 1.657 0.708–3.876 0.244 1.672 0.864 1.850 0.210 2 0.360 0.047–2.758 0.326 1.657 0.308–1.396 0.273 1.657 1.833 0.642–2.982 0.408 1.657 1.996 <t< td=""><td>EDSS >3 on baseline</td><td>1.058</td><td>0.575-1.949</td><td>0.856</td><td>1.071</td><td>0.054.1.050</td><td>0.010</td></t<>	EDSS >3 on baseline	1.058	0.575-1.949	0.856	1.071	0.054.1.050	0.010		
Relapse in year prior to baseline 0.868 0.385–1.960 0.734 Active lesions on MRI at baseline ^b	Number of relapses in year prior to baseline	1.379	0.952–1.999	0.090	1.271	0.874–1.850	0.210		
Active lesions on MRI at baseline" 1.657 0.708-3.876 0.244 1 0.360 0.047-2.758 0.326 2 0.655 0.308-1.396 0.273 Previous DMT 1.383 0.642-2.982 0.408 Type of previous DMT ^c U U U MET 1.287 0.580-2.853 0.535 HET 1.702 0.671-4.313 0.263	Relapse in year prior to baseline	0.868	0.385–1.960	0.734					
1 1.657 0.708=3.876 0.244 2 0.360 0.047=2.758 0.326 ≥3 0.655 0.308=1.396 0.273 Previous DMT 1.383 0.642=2.982 0.408 Type of previous DMT ^c U U MET 1.287 0.580=2.853 0.535 HET 1.702 0.671=4.313 0.263	Active lesions on MRI at baseline								
2 0.360 0.047-2.758 0.326 ≥3 0.655 0.308-1.396 0.273 Previous DMT 1.383 0.642-2.982 0.408 Type of previous DMT ^c	1	1.657	0.708-3.876	0.244					
≥3 0.655 0.308-1.396 0.273 Previous DMT 1.383 0.642-2.982 0.408 Type of previous DMT ^c	2	0.360	0.047-2.758	0.326					
Previous DMT 1.383 0.642-2.982 0.408 Type of previous DMT ^c	≥3 	0.655	0.308–1.396	0.273					
Type of previous DMT ⁻ MET 1.287 0.580-2.853 0.535 HET 1.702 0.671-4.313 0.263	Previous DMT	1.383	0.642-2.982	0.408					
MET 1.287 0.580-2.853 0.535 HET 1.702 0.671-4.313 0.263	Type of previous DMT								
HET 1.702 0.671-4.313 0.263	MET	1.287	0.580-2.853	0.535					
	HET	1.702	0.671-4.313	0.263					

NEDA-3-no evidence of disease activity (absence of relapses, EDSS progression and MRI activity). EDSS-expanded disability status scale. DMT-disease modifying therapy. MET-moderate efficacy therapies. HET-high efficacy therapies.

^a Male sex is reference category.

 $^{\rm b}\,$ No active lesions is reference category.

^c No DMT is reference category.

exposure was not associated with cladribine treatment outcomes (Petracca et al., 2022; Rammohan et al., 2012).

Reports on the long-term efficacy of cladribine in pwMS are limited and mainly come from follow-up of patients who participated in the initial randomized controlled trials. The CLARITY extension trial demonstrated that up to 75% of pwMS did not experience relapses after four years (Giovannoni et al., 2018). In the CLARINET-MS study longterm efficacy of cladribine tablets was established by following patients who participated in the initial phase III studies using data from the Italian MS registry (Patti et al., 2020). After 36 and 60 months 66.2% and 57.2% remained relapse-free, respectively, and the probability of being progression-free at 60 months after the last cladribine dose was 63.7%. A study from Israel showed that 68.9% (42/61) of the pwMS treated with cladribine tablets were relapse-free in year-3, and 82.9% (29/35) were relapse-free in year-4 (Magalashvili et al., 2022). A longer follow-up of our patient population, as well as populations from other cohort studies, is necessary to corroborate these results. This is of importance as cladribine tablets are registered for the treatment of highly active relapsing MS due to its profound effect on disease activity during the first two years of treatment with an expected efficacy of up to

Table 3

Adv	verse	events	recorded	in t	he f	irst	and	second	years	of	cladribine	treatmen	t.
-----	-------	--------	----------	------	------	------	-----	--------	-------	----	------------	----------	----

	year 1	year 2
Infections		
Urinary tract infections	7	
Oral herpes simplex	6	
COVID-19	4	1
Respiratory infection	3	
Herpes zoster	1	
Salmonellosis	1	
Breast abscess	1	
Penile warts	1	
Skin adverse events		
Hair loss	10	3
Rash	8	1
Gastric adverse events		
Nausea	3	1
Epigastric pain	3	
Hepatic lesion	2	
Diarrhea	1	
Cholecystitis	1	
Malignancies		
Breast cancer	1	
Melanoma	1	
Other		
Headache	4	1
Fatigue	2	
Hyperthyroidism	1	1
Anemia	1	1
Tachycardia	1	
Spontaneous abortion	1	
Musculoskeletal pain	1	
Intracerebral hematoma		1
Bleeding gums		1

four years post-treatment, and possibly beyond, due to its immune reconstitution properties (Giovannoni and Mathews, 2022). There is an expert consensus that selected patients who exhibit minimal disease activity in the period post cladribine treatment may receive additional courses although definite trials are missing (Habek et al., 2022; Meuth et al., 2022). As there is uncertainty on the exact approach to pwMS treated with cladribine tablets beyond four years, real-world studies are essential to provide data on the effectiveness of cladribine outside the confines of randomized controlled trials. This will only be revealed by long-term follow-up of real-world cohorts, like the one reported, which will aid in the development of future guidelines as well as coverage decisions (Real-World Evidence, 2022).

In our cohort, there were six pwMS who had non-active malignancies, one case of each of the following: cervical carcinoma, ovarian carcinoma, ovarian teratoma, testicular cancer, non-Hodgkin lymphoma, and breast cancer (Table S1). Although the pivotal cladribine tablet trials revealed a possible increase of malignancy risk in cladribinetreated pwMS, leading to the initial rejection of market authorization of cladribine in Europe, further meta-analysis and larger follow-up studies demonstrated no evidence of heightened cancer risk in pwMS treated with cladribine tablets (Pakpoor et al., 2015; Cook et al., 2019). As cladribine is administered as a short oral course with benefits that continue well beyond the dosing period it is suitable for pwMS with clinically and/or radiologically active disease and a positive history of malignant diseases as it does not cause prolonged immunosuppression, and therefore a possible increase in cancer risk, unlike continuously administered therapies such as B-cell monoclonal antibodies and sphingosine 1-phosphate (S1P) receptor modulators (Deeks, 2018). As well, because of its immune reconstitution properties, cladribine can be administered to pwMS with resolved infections that may become active with the administration of continuous immunosuppressive therapies, such as hepatitis B reactivation in ocrelizumab or fingolimod-treated pwMS (Ciardi et al., 2018; Lu et al., 2020). In the current cohort, there were three pwMS with resolved hepatitis B infection. Prior to cladribine initiation, all the patients were negative for hepatitis B DNA with two patients administering prophylactic therapy with lamivudine for up to 6 months after cladribine start, and one having regular HBV reactivation monitoring and no prophylactic therapy. None experienced reactivation of the infection. Six patients had latent tuberculosis with a positive QuantiFERON test and negative sputum analysis prior to cladribine start. Our protocol consisted of prophylactic therapy with isoniazid for 6 months with cladribine commencement after two weeks of isoniazid treatment.

We did not detect any cases of grade 4 lymphopenia in the pwMS with available data. In our cohort with 54.7% of pwMS had lymphopenia at month 2 and 35% at month 6. Grade 4 lymphopenia was present in a small number of pwMS in the initial CLARITY study, 0.7 vs. 0% of placebo recipients, and was more common in pwMS who had grade 3 lymphopenia when the drug was re-administered (Deeks, 2018). Similar to our cohort, the Finnish registry study did not record any grade 4 lymphopenia cases (Rauma et al., 2022). However, the authors reported 74.7% of patients with lymphopenia at any point during follow-up with higher grades (grade 2 and 3) being present in 57.2% of pwMS compared to 32% at month 2 and 15.9% at month 6 in our cohort (Rauma et al., 2022).

An integrated analysis of the safety of cladribine tablets revealed that the most common adverse event after lymphopenia was infections (Cook et al., 2019). The main infection that occurred more commonly in cladribine-treated patients than in the control group was herpes zoster, however, no systemic infections were noted (Cook et al., 2019). In our cohort, the most common infection was urinary tract infections followed by oral herpes and COVID-19 (Table 3). After infections, the second most common adverse event was skin problems, such as skin rash and hair loss. In a real-world study in Germany, 32% of cladribine-treated pwMS developed at least one skin reaction including skin rash, pruritus, mucositis, and hair thinning, however, the majority of patients continued cladribine treatment (Rolfes et al., 2021). The underlying mechanism of these changes may be toxicity or immune-mediated skin changes (Rolfes et al., 2021). As they are rarely considered in the safety management of pwMS treated with cladribine tablets real-world studies are important to raise awareness of this potential cladribine-related sideeffect.

This study has several limitations. Firstly, typical biases of a retrospective multicentric observational study (possible selection bias, heterogeneity in the clinical data collected between the different centers, heterogeneity in the population recruited, and in the clinical and neuroradiological follow-up protocols) may influence the results. Secondly, there was no systematic re-baselining of the patient's MRI after the start of treatment with cladribine tablets, which may have led to an overestimation of the radiological activity on follow-up. Thirdly, since patients were followed in different centers ascertainment bias is possible. However, we provide real-world cladribine effectiveness and safety data on a large multi-centric, multi-national cohort from Southeast European countries, from which there is very limited data on the treatment of MS. Furthermore, the use of the cladribine tablets in a very diverse patient population with many comorbidities and previous DMTs used adds a significant safety data to the currently existing literature.

In conclusion, the results of this study confirm the effectiveness of cladribine tablets in treating relapsing MS demonstrating that the majority of patients achieve NEDA-3 in the first and second year after cladribine initiation with age being a statistically significant positive predictor of achieving NEDA-3 at 12 months of follow-up. Longer follow-up is necessary to establish the durability of cladribine's effectiveness.

Author statements

MH, IA, BB, TG, MKS: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals, TG Pharmaceuticals.



Fig. 2. Lymphocyte values before, 2, and 6 months after the start of the treatment. Lymphocyte values are expressed per μ L with a comparison of values at baseline and month 2 on the upper, baseline and month 6 in the middle, and month 2 and month 6 on the lower graph.

CR participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Merck, Novartis, Sanofi Genzyme, Roche, Teva.

VBK: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Pliva/ Teva, Roche.

TG: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Novartis, Merck, Medis, Pliva, Boerhinger, Belupo, Roche, Krka, Sanofi, Abboth, Zentiva.

JR: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Zentiva, Novartis, Roche, Biogen, Merck, Sanofi, Pliva/Teva.

IL: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Novartis, Roche, Merck, Biogen, Sanofi, Pliva.

IC, AA, PK, SG: Nothing to disclose.

LJR: Participated as a clinical investigator and/or serves on scientific advisory boards and/or speaker fees from: Merck, Bayer, Novartis, Biogen, Sanofi Genzyme, Teva, Roche.

JD: Serves on scientific advisory boards for Bayer, Biogen, Medis, Merck, Novartis, Roche, Sanofi-Genzyme, Janssen and Teva and have received speaker bureaus for Biogen, Bayer, Merck, Roche, Sanofi-Genzyme, Janssen, Medis, Hemofarm, Medtronic, Zentiva, and Teva.

TP: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Teva, Hemofarm, Roche, TG Pharmaceuticals.

ŠM: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Teva, Hemofarm, Roche, TG Pharmaceuticals.

Funding

No funding was received.

Declaration of Competing Interest

None.

Data availability

Data from this study not published within this article are available upon reasonable request for any qualified investigator.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jneuroim.2023.578164.

References

- Baker, D., Pryce, G., Herrod, S.S., Schmierer, K., 2019. Potential mechanisms of action related to the efficacy and safety of cladribine. Mult. Scler. Relat. Disord. 30, 176–186. https://doi.org/10.1016/j.msard.2019.02.018.
- Bose, G., Rush, C., Atkins, H.L., Freedman, M.S., 2021. A real-world single-Centre analysis of alemtuzumab and cladribine for multiple sclerosis. Mult. Scler. Relat. Disord. 52, 102945 https://doi.org/10.1016/j.msard.2021.102945.
- Ciardi, M.R., Iannetta, M., Zingaropoli, M.A., et al., 2018 Dec 26. Reactivation of hepatitis B virus with immune-escape mutations after Ocrelizumab treatment for multiple sclerosis. Open Forum. Infect. Dis. 6 (1), ofy356. https://doi.org/10.1093/ ofid/ofy356 (PMID: 30697576; PMCID: PMC6343960).
- Cook, S., Leist, T., Comi, G., et al., 2019 Apr. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult. Scler. Relat. Disord.

29, 157–167. https://doi.org/10.1016/j.msard.2018.11.021. Epub 2018 Nov 20. PMID: 30885374.

- Deeks, E.D., 2018 Aug. Cladribine tablets: a review in relapsing MS. CNS Drugs 32 (8), 785–796. https://doi.org/10.1007/s40263-018-0562-0. Erratum in: CNS Drugs. 2019 Feb;33(2):193. PMID: 30105527; PMCID: PMC6353806.
- European Medicines Agency, 2022. Mavenclad, INN-cladribine [summary of product characteristics]. https://www.ema.europa.eu/en/documents/product-information_n/mavenclad-epar-product-information_en.pdf. Accessed on 28 December 2022.
- Giovannoni, G., Mathews, J., 2022 Jun. Cladribine tablets for relapsing-remitting multiple sclerosis: a Clinician's review. Neurol. Ther. 11 (2), 571–595. https://doi org/10.1007/s40120-022-00339-7 (Epub 2022 Mar 23. PMID: 35318617; PMCID: PMC8940595).
- Giovannoni, G., Comi, G., Cook, S., et al., 2010. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362 (5), 416–426. https://doi.org/10.1056/NEJMoa0902533.
- Giovannoni, G., Cook, S., Rammohan, K., et al., 2011 Apr. CLARITY study group. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 10 (4), 329–337. https://doi.org/10.1016/S1474-4422(11)70023-0. PMID: 21397565.
- Giovannoni, G., Soelberg Sorensen, P., Cook, S., et al., 2018. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult. Scler. 24 (12), 1594–1604. https://doi.org/10.1177/1352458517727603.
- Habek, M., Drulovic, J., Brecl Jakob, G., et al., 2022 Nov 17. Treatment with Cladribine tablets beyond year 4: a position statement by southeast European multiple sclerosis centers. Neurol. Ther. 1–13. https://doi.org/10.1007/s40120-022-00422-z (Epub ahead of print. PMID: 36394714; PMCID: PMC9672547).
- Lizak, N., Hodgkinson, S., Butler, E., et al., 2021. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy. Mult. Scler. 27 (3), 465–474. https://doi.org/10.1177/1352458520921087.
- Lu, M.C., Shih, Y.L., Hsieh, T.Y., Lin, J.C., 2020 Apr. Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis. J. Formos. Med. Assoc. 119 (4), 886–887. https://doi.org/10.1016/j.jfma.2019.10.012. Epub 2019 Oct 31. PMID: 31679907.
- Magalashvili, D., Mandel, M., Dreyer-Alster, S., Didikin, M., Harari, G., Flechter, S., Achiron, A., 2022 Nov 15. Cladribine treatment for highly active multiple sclerosis: real-world clinical outcomes for years 3 and 4. J. Neuroimmunol. 372, 577966. https://doi.org/10.1016/j.jneuroim.2022.577966.
- Meuth, S.G., Bayas, A., Kallmann, B., Linker, R., et al., 2022 Sep. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert. Opin. Pharmacother. 23 (13), 1503–1510. https://doi.org/10.1080/ 14656566.2022.2106783. Epub 2022 Aug 5. PMID: 35930260.
 Pakpoor, J., Disanto, G., Altmann, D.R., et al., 2015 Oct 1. No evidence for higher risk of
- Pakpoor, J., Disanto, G., Altmann, D.R., et al., 2015 Oct 1. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol. Neuroimmunol. Neuroinflamm. 2 (6), e158 https://doi.org/10.1212/NXI.0000000000000158. PMID: 26468472; PMCID: PMC4592538.
- Patti, F., Visconti, A., Capacchione, A., Roy, S., Trojano, M., CLARINET-MS Study Group, 2020. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther. Adv. Neurol. Disord. 13 https://doi.org/10.1177/1756286420922685, 1756286420922685.
- Petracca, M., Ruggieri, S., Barbuti, E., et al., 2022 Sep. Predictors of Cladribine effectiveness and safety in multiple sclerosis: a real-world, multicenter, 2-year follow-up study. Neurol. Ther. 11 (3), 1193–1208. https://doi.org/10.1007/s40120-022-00364-6 (Epub 2022 Jun 2. PMID: 35653061; PMCID: PMC9338179).
- Pfeuffer, S., Rolfes, L., Hackert, J., et al., 2022. Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres. Mult. Scler. 28 (2), 257–268. https://doi.org/10.1177/13524585211012227.
- Rammohan, K., Giovannoni, G., Comi, G., et al., 2012 Jan. CLARITY (CLAdRIbine tablets treating multiple sclerosis orally) study group. Cladribine tablets for relapsingremitting multiple sclerosis: efficacy across patient subgroups from the phase III CLARITY study. Mult. Scler. Relat. Disord. 1 (1), 49–54. https://doi.org/10.1016/j. msard.2011.08.006. Epub 2011 Sep 15. PMID: 25876451.
- Rauma, I., Viitala, M., Kuusisto, H., et al., 2022. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult. Scler. Relat. Disord. 61, 103755 https://doi.org/10.1016/j.msard.2022.103755.
- Real-World Evidence, 2022. FDA. https://www.fda.gov/science-research/science-and -research-specialtopics/real-world-evidence. Accessed on 12 January 2023.
- Rolfes, L., Pfeuffer, S., Hackert, J., et al., 2021 Apr 9. Skin reactions in patients with multiple sclerosis receiving Cladribine treatment. Neurol. Neuroimmunol. Neuroinflamm. 8 (3), e990 https://doi.org/10.1212/NXI.00000000000990. PMID: 33837059; PMCID: PMC8042777.
- Tremlett, H., Zhao, Y., Joseph, J., Devonshire, V., Clinic, U.B.C.M.S., Neurologists., 2008 Dec. Relapses in multiple sclerosis are age- and time-dependent. J. Neurol. Neurosurg. Psychiatry 79 (12), 1368–1374. https://doi.org/10.1136/ jnnp.2008.145805 (Epub 2008 Jun 5. PMID: 18535026).